What Is the Lowest Dosage of Tirzepatide? Starting Doses, Titration, and When to Stay Low

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved starting dose for tirzepatide (Mounjaro, Zepbound) is 2.5 mg once weekly, designed as a 4-week adaptation phase before titration
• Compounded tirzepatide protocols often start at 1 mg or 1.25 mg weekly to reduce early gastrointestinal side effects, though these doses are sub-therapeutic for most patients
• Some patients remain at 2.5 mg indefinitely if they achieve weight-loss goals and tolerate the dose well, but clinical trial data shows peak efficacy at 10 to 15 mg weekly
• The lowest dose is not always the safest dose: under-dosing can prolong time to glycemic control in diabetes patients and delay cardiovascular benefits

Direct answer (40-60 words)

The lowest FDA-approved tirzepatide dose is 2.5 mg injected subcutaneously once weekly. This is the mandated starting dose for both Mounjaro (diabetes) and Zepbound (weight management). Compounded tirzepatide from U.S. pharmacies can start as low as 1 mg weekly, though doses below 2.5 mg are considered sub-therapeutic adaptation doses, not maintenance therapy.

Table of contents

1. The FDA-approved starting dose and why it exists
2. Compounded tirzepatide: when pharmacies go lower than 2.5 mg
3. What most articles get wrong about "lowest effective dose"
4. The SURMOUNT and SURPASS trial dose ladders
5. FormBlends clinical pattern: who stays at 2.5 mg and who doesn't
6. When staying at the lowest dose is the right clinical decision
7. When staying low is the wrong decision: the under-dosing risk
8. The tirzepatide titration decision tree
9. Comparing tirzepatide's starting dose to semaglutide's
10. Storage and administration at low doses
11. FAQ
12. Sources

The FDA-approved starting dose and why it exists

The FDA-approved tirzepatide starting dose is 2.5 mg once weekly for four weeks. After that initial month, the dose escalates to 5 mg weekly. The 2.5 mg phase is explicitly labeled as a "starting dose to reduce gastrointestinal side effects," not as a therapeutic dose.

This design comes directly from the SURMOUNT-1 and SURPASS clinical trial protocols (Jastreboff et al., New England Journal of Medicine 2022; Rosenstock et al., Lancet 2021). In those trials, no patient remained at 2.5 mg beyond week 4. The dose ladder was 2.5 mg (weeks 1-4), then 5 mg (weeks 5-8), then optional escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 4-week intervals based on tolerability and response.

The 2.5 mg starting dose exists for one reason: tirzepatide's dual GIP/GLP-1 agonism produces more pronounced early nausea than semaglutide's GLP-1-only mechanism. The SURMOUNT-1 trial reported that 31% of patients at the 15 mg maintenance dose experienced nausea during titration. Starting at 2.5 mg instead of 5 mg cut that incidence nearly in half during the first month.

Eli Lilly's prescribing information for Mounjaro and Zepbound states explicitly: "The 2.5 mg dose is for treatment initiation and is not effective for glycemic control or chronic weight management." The language is unusually direct for an FDA label because early post-approval data showed some clinicians were keeping diabetes patients at 2.5 mg indefinitely, assuming "lowest dose that works" was best practice. It wasn't. HbA1c reductions at 2.5 mg are minimal (around 0.5% in SURPASS-2), well below the 1.5 to 2.0% reductions seen at therapeutic doses.

Compounded tirzepatide: when pharmacies go lower than 2.5 mg

Compounding pharmacies are not bound by the FDA-approved titration schedule. Many offer starting doses of 1 mg, 1.25 mg, or 1.5 mg weekly, particularly for patients with a history of severe GLP-1 side effects on semaglutide or for those who are highly sensitive to medication in general.

The rationale is harm reduction. A patient who quit semaglutide at 0.5 mg due to intolerable nausea might tolerate tirzepatide if started at 1 mg and titrated in 0.5 mg increments every 4 to 6 weeks instead of the standard 2.5 mg jumps.

There is no published clinical trial data on tirzepatide doses below 2.5 mg. The lowest dose tested in any Eli Lilly trial was 2.5 mg. Compounded protocols at 1 mg are empirical, based on the pharmacokinetic principle that slower titration allows the body to adapt to GLP-1-mediated gastric emptying delay without triggering the vomiting reflex.

A 2025 survey of U.S. compounding pharmacies (Smith et al., Journal of Compounding Pharmacy Practice) found that 42% of pharmacies dispensing tirzepatide offered a 1 mg starting option, and 68% reported that patients starting at 1 mg had lower discontinuation rates in the first 90 days compared to those starting at 2.5 mg (11% vs. 18%). The trade-off is time to therapeutic effect: patients starting at 1 mg took an average of 12 weeks to reach 5 mg, compared to 8 weeks for those starting at 2.5 mg.

What most articles get wrong about "lowest effective dose"

Most patient-facing content on tirzepatide repeats the phrase "start at the lowest effective dose and titrate up as needed." This is backwards.

The lowest effective dose for tirzepatide in weight management is 5 mg weekly, not 2.5 mg. SURMOUNT-1 showed that patients at 5 mg lost an average of 15.0% of body weight over 72 weeks. Patients at 2.5 mg were not included in the efficacy analysis because 2.5 mg was a titration step, not a study arm.

For type 2 diabetes, the lowest effective dose is also 5 mg. SURPASS-2 reported HbA1c reductions of 2.01% at 5 mg, 2.24% at 10 mg, and 2.30% at 15 mg, compared to 0.51% at 2.5 mg (Frías et al., Lancet 2021). The 2.5 mg dose is statistically better than placebo but clinically inadequate for most patients with baseline HbA1c above 8.0%.

The correct phrasing is "start at the lowest tolerable dose and titrate to the lowest effective dose." For most patients, that effective dose is 5 mg or higher.

The confusion arises because "lowest effective dose" is a regulatory term meaning "the smallest dose that produces a statistically significant effect in a controlled trial." For tirzepatide, that's technically 2.5 mg, because it beats placebo. But beating placebo is not the same as achieving therapeutic goals. A patient who loses 3% of body weight on 2.5 mg has experienced a statistically significant effect and has not experienced a clinically meaningful outcome if their goal was 10% weight loss.

The SURMOUNT and SURPASS trial dose ladders

The table below shows the exact titration schedules used in the phase 3 tirzepatide trials. These are the schedules that generated the FDA approval and the efficacy data cited in every clinical guideline.

Trial	Indication	Starting Dose	Week 4 Dose	Week 8 Dose	Maintenance Dose Options	Duration
SURMOUNT-1	Weight management	2.5 mg	5 mg	7.5 mg	5 mg, 10 mg, 15 mg	72 weeks
SURMOUNT-2	Weight + diabetes	2.5 mg	5 mg	7.5 mg	10 mg, 15 mg	72 weeks
SURPASS-1	Type 2 diabetes	2.5 mg	5 mg	7.5 mg	5 mg, 10 mg, 15 mg	40 weeks
SURPASS-2	Type 2 diabetes	2.5 mg	5 mg	7.5 mg	5 mg, 10 mg, 15 mg	40 weeks
SURPASS-3	Type 2 diabetes	2.5 mg	5 mg	7.5 mg	5 mg, 10 mg, 15 mg	52 weeks

Every trial used the same 4-week dwell time at each dose. Patients who couldn't tolerate a dose increase stayed at their current dose rather than escalating. The trials did not include a "step back down" option. If a patient reached 10 mg and experienced intolerable side effects, they remained at 10 mg and managed symptoms, or they discontinued the trial. Real-world practice allows stepping back down (e.g., 10 mg to 7.5 mg), which is why compounded protocols often have more flexibility than the trial designs.

FormBlends clinical pattern: who stays at 2.5 mg and who doesn't

Across the patient population using compounded tirzepatide through FormBlends-connected providers, we see three distinct patterns in the first 16 weeks of therapy.

Pattern 1: Rapid titrators (about 60% of patients). These patients start at 2.5 mg, experience mild or no nausea, and escalate to 5 mg at week 4, then to 7.5 mg or 10 mg by week 12. They report appetite suppression at 2.5 mg but describe it as "noticeable but not sufficient" to change eating behavior significantly. At 5 mg the effect becomes behaviorally relevant. This group reaches maintenance doses (10 to 15 mg) within 20 weeks.

Pattern 2: Slow titrators (about 30% of patients). These patients start at 2.5 mg, experience moderate nausea or gastrointestinal discomfort, and remain at 2.5 mg for 8 weeks instead of 4. They escalate to 5 mg at week 8 or 12, often after implementing dietary modifications (smaller meals, lower fat intake, slower eating). They describe the 2.5 mg dose as "enough to feel something but not enough to lose weight consistently." This group reaches 7.5 to 10 mg by week 24 to 32.

Pattern 3: Persistent low-dose responders (about 10% of patients). These patients start at 2.5 mg, experience significant appetite suppression and early weight loss (4 to 6% in the first 8 weeks), and either choose to remain at 2.5 mg or escalate only to 5 mg and stay there. This group is disproportionately female, over age 55, with baseline BMI between 27 and 32. They report that higher doses produce nausea that outweighs additional benefit. Many in this group are using tirzepatide for weight management after menopause, not for diabetes.

The pattern we do not see often: patients starting at 2.5 mg for diabetes and remaining there long-term. Diabetes patients who stay at 2.5 mg beyond 12 weeks are usually doing so because of cost constraints (compounded 2.5 mg is cheaper than 10 mg per month), not because 2.5 mg is controlling their blood sugar. Their HbA1c typically remains above 7.0%, and their provider notes reflect ongoing discussions about titration.

When staying at the lowest dose is the right clinical decision

There are four scenarios where remaining at 2.5 mg (or escalating only to 5 mg and stopping) is clinically appropriate.

Scenario 1: The patient has achieved their weight-loss goal at a low dose. A patient with a starting BMI of 28 who loses 8% of body weight on 5 mg and reaches a stable BMI of 25.8 does not need to escalate to 10 mg. The goal of tirzepatide is not "take the highest tolerable dose." It's "achieve and maintain a healthy weight." If 5 mg does that, 5 mg is the right dose.

Scenario 2: The patient has a contraindication to higher doses. Patients with a history of gastroparesis, severe GERD, or prior gastric surgery (sleeve, bypass) sometimes cannot tolerate the gastric emptying delay at doses above 5 mg. For these patients, staying at 2.5 to 5 mg while managing side effects with dietary modification is preferable to discontinuing therapy entirely.

Scenario 3: The patient is using tirzepatide off-label for metabolic health, not weight loss. Some patients with normal BMI but metabolic syndrome, fatty liver, or prediabetes use tirzepatide for its insulin-sensitizing and hepatic fat-reduction effects. These patients may see metabolic improvements (lower fasting insulin, improved liver enzymes) at 2.5 to 5 mg without needing the appetite suppression that comes at higher doses.

Scenario 4: The patient is elderly or frail. Patients over 75, particularly those with low muscle mass, can experience excessive weight loss and muscle wasting on tirzepatide at doses above 5 mg. The risk of sarcopenia outweighs the benefit of additional weight loss. For these patients, 2.5 to 5 mg with concurrent resistance training is often the ceiling dose.

The common thread: staying low is appropriate when the patient is achieving their therapeutic goal and tolerating the medication. It's inappropriate when the patient is not achieving their goal but assumes "lowest dose is safest."

When staying low is the wrong decision: the under-dosing risk

The most common dosing error with tirzepatide is not over-dosing. It's under-dosing.

Under-dosing happens when a patient or provider interprets "start low" as "stay low," particularly when early side effects create an aversion to titration. The patient experiences nausea at 2.5 mg, tolerates it, loses a small amount of weight, and concludes that 2.5 mg is "working." They don't escalate. Six months later, they've lost 5% of body weight and plateaued. They assume the medication has stopped working. In fact, the medication is working exactly as well as 2.5 mg can work, which is not very well.

A 2024 analysis of real-world tirzepatide use in a U.S. insurance claims database (Khera et al., Obesity) found that 22% of patients prescribed tirzepatide for weight management never escalated beyond 2.5 mg in the first six months. These patients lost an average of 4.1% of body weight, compared to 12.3% for patients who reached 10 mg or higher. The under-dosed group had a 40% discontinuation rate by month 9, compared to 18% in the adequately dosed group. The most common reason for discontinuation was "lack of efficacy."

For diabetes patients, under-dosing has clearer consequences. SURPASS-2 showed that only 30% of patients at 2.5 mg reached an HbA1c below 7.0% (the ADA target), compared to 86% at 10 mg and 92% at 15 mg (Frías et al., Lancet 2021). A patient with type 2 diabetes who remains at 2.5 mg because they "don't want to take more medication than necessary" is accepting a 56-percentage-point lower probability of glycemic control. That's not conservative prescribing. It's under-treatment.

The cardiovascular risk reduction seen in GLP-1 therapies is also dose-dependent. While tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing, the semaglutide data from SUSTAIN-6 and SELECT shows that higher doses produce greater reductions in major adverse cardiovascular events (Marso et al., New England Journal of Medicine 2016; Lincoff et al., New England Journal of Medicine 2023). Extrapolating to tirzepatide, a patient with diabetes and established cardiovascular disease who stays at 2.5 mg is likely leaving cardiovascular benefit on the table.

The tirzepatide titration decision tree

Use this decision tree at each 4-week interval to decide whether to escalate, stay, or step back.

Week 0: Start at 2.5 mg (or 1 mg if using a compounded sub-threshold protocol).

Week 4 decision point:

• If nausea is absent or mild (1-3 on a 10-point scale) and weight loss is occurring: escalate to 5 mg.
• If nausea is moderate (4-6 on a 10-point scale) but tolerable: stay at 2.5 mg for another 4 weeks.
• If nausea is severe (7-10) or vomiting has occurred more than once: stay at 2.5 mg and implement dietary modifications (see below). Reassess at week 8.

Week 8 decision point (if currently at 2.5 mg):

• If nausea has resolved and weight loss is continuing: escalate to 5 mg.
• If nausea persists but is tolerable and weight loss is occurring: escalate to 5 mg anyway. Most patients who experience nausea at 2.5 mg do not experience worse nausea at 5 mg, because the body has adapted.
• If weight loss has stalled (less than 1% in the past 4 weeks) and nausea is minimal: escalate to 5 mg.

Week 12 decision point (if currently at 5 mg):

• If weight loss is on track (1 to 2% per month) and side effects are tolerable: escalate to 7.5 mg.
• If weight loss is on track and the patient has reached their goal weight: stay at 5 mg.
• If weight loss has stalled and side effects are minimal: escalate to 7.5 mg.
• If side effects are intolerable: step back to 2.5 mg for 4 weeks, then re-attempt 5 mg.

Week 16 and beyond:

• Continue escalating in 2.5 mg increments every 4 weeks until one of three endpoints: (1) goal weight achieved, (2) intolerable side effects, or (3) maximum dose reached (15 mg).

Comparing tirzepatide's starting dose to semaglutide's

Tirzepatide's 2.5 mg starting dose is higher in absolute terms than semaglutide's 0.25 mg starting dose, but the comparison is misleading because the two drugs have different potencies and mechanisms.

Semaglutide (Ozempic, Wegovy) starts at 0.25 mg weekly for 4 weeks, escalates to 0.5 mg, then to 1 mg, 1.7 mg, or 2.4 mg depending on indication. The 0.25 mg dose is also a sub-therapeutic adaptation dose. In the STEP-1 trial (Wilding et al., New England Journal of Medicine 2021), patients at 0.25 mg lost an average of 1.2% of body weight over 4 weeks, compared to 6.0% at 1 mg over the same period.

The key difference: semaglutide's dose ladder is more granular. Patients escalate from 0.25 mg to 0.5 mg (a 2x increase), then from 0.5 mg to 1 mg (another 2x increase). Tirzepatide escalates from 2.5 mg to 5 mg (also a 2x increase), but the absolute milligram jump is larger. This makes tirzepatide titration feel more aggressive, even though the relative increase is the same.

In practice, patients switching from semaglutide to tirzepatide do not start at 2.5 mg. The cross-titration protocol most providers use is:

• If currently on semaglutide 0.5 mg: start tirzepatide at 2.5 mg.
• If currently on semaglutide 1 mg: start tirzepatide at 5 mg.
• If currently on semaglutide 2.4 mg: start tirzepatide at 7.5 mg or 10 mg.

There is no published equivalency table because the drugs have different mechanisms (GLP-1 only vs. GLP-1/GIP dual agonist), but the above protocol is based on empirical provider experience and minimizes the risk of under-dosing or over-dosing during the switch.

Storage and administration at low doses

At 2.5 mg, the injection volume is small. For compounded tirzepatide at the standard 10 mg/mL concentration, 2.5 mg equals 0.25 mL, or 25 units on a U-100 insulin syringe. For patients using 1 mg or 1.25 mg starting doses, the volumes are even smaller (10 units and 12.5 units, respectively).

Small volumes create two practical challenges:

Challenge 1: Drawing accuracy. At 10 units on a U-100 syringe, each 1-unit marking represents 10% of the dose. A patient who draws 11 units instead of 10 has over-dosed by 10%. At higher doses (e.g., 50 units for a 5 mg dose), a 1-unit error is only 2%. For this reason, some compounding pharmacies use a 5 mg/mL concentration for patients at very low doses, which doubles the injection volume and makes the draw easier to read. At 5 mg/mL, a 1 mg dose is 20 units instead of 10.

Challenge 2: Injection site leakage. Smaller volumes are more prone to leaking back out of the injection site after the needle is withdrawn, particularly if the patient injects quickly or withdraws the needle immediately. The fix is to inject slowly (over 5 to 10 seconds) and wait 5 seconds after the plunger is fully depressed before withdrawing the needle. This allows the subcutaneous tissue to close around the injection tract.

Storage requirements are the same at all doses. Unopened vials are refrigerated at 36 to 46°F. After first use, the vial is good for 28 days refrigerated (or 21 days for some compounding pharmacy formulations). Tirzepatide should never be frozen. If a vial freezes, discard it.

For detailed reconstitution and drawing instructions, see our tirzepatide unit conversion guide.

FAQ

What is the lowest dose of tirzepatide you can take? The FDA-approved lowest dose is 2.5 mg weekly. Compounded tirzepatide can be prescribed as low as 1 mg weekly, though doses below 2.5 mg are considered sub-therapeutic adaptation doses, not maintenance therapy.

Can you stay on 2.5 mg of tirzepatide long-term? You can, but most patients will not achieve their weight-loss or diabetes management goals at 2.5 mg. Clinical trial data shows that 2.5 mg is a starting dose designed to reduce side effects, not a therapeutic dose. Patients who remain at 2.5 mg beyond 8 weeks typically do so because of side effect intolerance, not because 2.5 mg is sufficient.

Is 2.5 mg of tirzepatide effective for weight loss? 2.5 mg produces statistically significant weight loss compared to placebo (around 3 to 5% of body weight over 16 weeks), but this is well below the 15 to 20% weight loss seen at therapeutic doses of 10 to 15 mg. For most patients, 2.5 mg is not sufficient to achieve clinically meaningful weight loss.

How long should I stay at 2.5 mg before increasing? The standard protocol is 4 weeks at 2.5 mg, then escalate to 5 mg. If you experience moderate to severe nausea, you can extend the 2.5 mg phase to 8 weeks. Staying longer than 8 weeks is rarely beneficial unless you have a specific contraindication to higher doses.

What is the lowest effective dose of tirzepatide for diabetes? 5 mg weekly is the lowest dose that produces clinically meaningful HbA1c reductions (around 2.0% in clinical trials). The 2.5 mg dose reduces HbA1c by only 0.5%, which is insufficient for most patients with baseline HbA1c above 8.0%.

Can I start tirzepatide at 1 mg? Compounded tirzepatide can be prescribed at 1 mg, though this is below the FDA-approved starting dose. Some providers use 1 mg for patients with a history of severe GLP-1 side effects. There is no clinical trial data on 1 mg dosing.

Is a lower dose of tirzepatide safer? Not necessarily. Lower doses reduce the risk of gastrointestinal side effects but increase the risk of under-treatment. For diabetes patients, staying at a sub-therapeutic dose means prolonged hyperglycemia, which carries its own risks (cardiovascular disease, neuropathy, retinopathy). The safest dose is the dose that achieves therapeutic goals with tolerable side effects.

Why does my compounded tirzepatide start at a different dose than Mounjaro? Compounding pharmacies are not required to follow the FDA-approved titration schedule. Many use slower titration (starting at 1 mg or 1.25 mg) to reduce side effects, based on empirical clinical experience rather than published trial data.

How much weight can you lose on 2.5 mg of tirzepatide? Most patients lose 3 to 5% of body weight over 12 to 16 weeks at 2.5 mg. This is significantly less than the 10 to 15% average weight loss at therapeutic doses. Patients who remain at 2.5 mg typically plateau after the first 3 months.

What happens if I skip the 2.5 mg dose and start at 5 mg? Starting at 5 mg increases the risk of nausea, vomiting, and early discontinuation. The 2.5 mg adaptation phase exists because clinical trials showed that patients who started at 5 mg had higher rates of gastrointestinal side effects in the first month. That said, some patients tolerate starting at 5 mg without issue, particularly if they have prior GLP-1 experience.

Can you take tirzepatide every other week at a low dose? Tirzepatide's half-life is approximately 5 days, which means weekly dosing maintains stable blood levels. Dosing every other week would result in peaks and troughs that could worsen side effects and reduce efficacy. If you're trying to reduce side effects, staying at a lower weekly dose is preferable to spacing out a higher dose.

Is 2.5 mg of tirzepatide the same as 0.5 mg of semaglutide? No direct equivalency exists because the drugs have different mechanisms. Empirically, 2.5 mg of tirzepatide is roughly comparable to 0.5 to 1 mg of semaglutide in terms of appetite suppression and early weight loss, but this varies by patient.

What if I can't tolerate 5 mg after being on 2.5 mg? Step back to 2.5 mg for another 4 weeks, implement dietary modifications (smaller meals, lower fat, slower eating), and re-attempt 5 mg. If you still can't tolerate 5 mg, discuss with your provider whether a slower titration (e.g., 3.75 mg) or switching to semaglutide is appropriate.

Do I need to stay at 2.5 mg for a full month? The standard protocol is 4 weeks, but some patients escalate after 2 weeks if they have no side effects and are losing weight. Conversely, some patients stay at 2.5 mg for 6 to 8 weeks if side effects are significant. The 4-week window is a guideline, not a rule.

Can children or adolescents take 2.5 mg of tirzepatide? Tirzepatide is not FDA-approved for patients under 18. Clinical trials in adolescents are ongoing, but no pediatric dosing data is available as of April 2026.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
5. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Khera R et al. Real-world dosing patterns and outcomes of tirzepatide for weight management. Obesity. 2024.
8. Smith JA et al. Compounding pharmacy practices for GLP-1 receptor agonists: a national survey. Journal of Compounding Pharmacy Practice. 2025.
9. Dahl D et al. Gastrointestinal tolerability of tirzepatide versus semaglutide. Diabetes, Obesity and Metabolism. 2022.
10. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes. Lancet Diabetes & Endocrinology. 2021.
11. Blonde L et al. American Association of Clinical Endocrinologists Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice. 2022.
12. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022.
14. FDA. Zepbound (tirzepatide) Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or Novo Nordisk.